The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)

被引：0
作者：
Juan Zhao
Wei Zhou
Yangfeng Wu
Ping Ji
Li Yang
Xiaoyan Yan
Zhuoli Zhang
机构：
[1] Peking University First Hospital,Department of Rheumatology and Clinical Immunology
[2] Peking University Clinical Research Institute (PUCRI),undefined
[3] Peking University School of Public Health,undefined
来源：
BMC Medical Informatics and Decision Making | / 21卷
关键词：
Rheumatoid arthritis; Pharmaceutical economics analysis; Cost-effectiveness analysis; Cost-utility analysis; Relapse;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 82 条
[1]  
Katchamart W(2009)Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis Ann Rheum Dis 68 1105-1112
[2]  
Trudeau J(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis 79 685-699
[3]  
Phumethum V(2014)Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial Lancet 383 321-332
[4]  
Bombardier C(2011)A new chance to maintain remission induced by anti-TNF agents in rheumatoid arthritis patients: CYnAR study II of a 12-month follow-up Int J Immunopathol Pharmacol 24 167-174
[5]  
Smolen JS(2009)Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis Joint Bone Spine 76 350-355
[6]  
Landewé RBM(2011)Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study Ann Rheum Dis 70 1389-94
[7]  
Bijlsma JWJ(2013)Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis Clin Ther 35 1850-1861
[8]  
Burmester GR(2013)Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial Lancet 381 918-929
[9]  
Dougados M(2005)A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal Rheumatology 44 1414-1421
[10]  
Kerschbaumer A(1996)Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications N Engl J Med 334 1287-1291
123456789